Researchers in Singapore have developed a fluorescent nanosensor capable of detecting indole-3-propionic acid within minutes, potentially supporting faster gut microbiome research and diagnostic testing.

Researchers in Singapore have developed what is reported to be the first optical nanosensor specifically designed to detect indole-3-propionic acid (IPA), a gut microbiome-derived metabolite that is attracting increasing interest as a potential biomarker for a range of health conditions.

The fluorescent nanosensor was developed through a collaboration involving the National Institute of Education at Nanyang Technological University, the Singapore-MIT Alliance for Research and Technology, National University Hospital and the National University of Singapore.

According to the research team, the technology enables rapid optical detection of IPA, offering a faster alternative to conventional laboratory testing approaches.

IPA is produced by gut microbiota and has been associated in scientific research with inflammation, metabolic disorders and other chronic diseases. Researchers believe improved methods for measuring the biomarker could support a better understanding of the relationship between the gut microbiome and human health.

Current approaches for detecting IPA often rely on mass spectrometry-based techniques, which typically require specialised laboratory equipment, technical expertise and extended processing times.

The newly developed nanosensor generates optical readouts within minutes, potentially simplifying the detection process and improving accessibility for researchers studying microbiome-related biology.

While the technology remains at the research stage, it may provide a foundation for future diagnostic applications subject to further validation and regulatory requirements.

Commenting on the development, Nidhi Bharti, medical devices analyst at GlobalData, said: “The innovation represents a significant step forward in gut microbiome research and precision diagnostics. As evidence linking gut microbiome activity to gastrointestinal and metabolic conditions continues to evolve, demand for diagnostic solutions that provide timely and clinically actionable insights will rise.”

The development also reflects growing interest in precision medicine approaches that utilise biomarkers to support disease monitoring and personalised treatment strategies.

Bharti added: “Beyond diagnostics, the platform may support pharmaceutical and therapeutic research by enabling functional studies of microbiome-related interventions, probiotics, and novel treatment strategies.”

According to GlobalData, technologies that can simplify biomarker assessment may become increasingly important as healthcare systems seek to expand preventive care and personalised medicine programmes.

Bharti said: “The broader significance of this innovation lies in its potential to bridge the gap between laboratory-based biomarker analysis and real-world clinical application. As healthcare systems increasingly prioritize preventive care and personalized treatment pathways, technologies that enable faster and more convenient biomarker assessment are expected to gain substantial attention.”

Although additional validation will be required before any clinical deployment, the nanosensor highlights ongoing efforts to develop practical tools that could improve the speed and accessibility of biomarker testing in both research and healthcare settings.